

Pharmaceutical Strategy – Timely patient access to affordable medicines: Part II - Public Consultation

Deadline: Tuesday 15 September midnight CEST

ORGANISATIONAL INPUTS NEEDED FROM AS MANY AS POSSIBLE


This is a key opportunity to make sure that paediatric haemato-oncology is not overlooked in the EU agenda, We invite being straightforward in requesting that children & adolescents needs are allocated within the pharmaceutical strategy. Your responses and spreading the information within your networks is key to maximise the number of replies on childhood cancer issues.

GUIDANCE ON HOW TO PROVIDE YOUR INPUTS

STEP 1. Create an account on EU Health Policy Platform (required to be able to submit comment)

1a. Go to: <https://webgate.ec.europa.eu/cas/eim/external/register.cgi>

1b. Fill in form



1c. Create password (activation link will be sent to your email address)

Confirmation email on newly created account may take up to 24 hours to receive!

STEP 2: Access the Pharmaceutical Strategy Roadmap Consultation

2a. Go to:

<https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12421-Pharmaceutical-Strategy-Timely-patient-access-to-affordable-medicines>

Scroll below through the page where written “Public Consultation”

Pharmaceuticals – safe and affordable medicines (new EU strategy)

Have your say > Published initiatives > Pharmaceuticals – safe and affordable medicines (new EU strategy)

Roadmap

Feedback period
02 June 2020 - 07 July 2020

FEEDBACK: CLOSED

Public consultation

Feedback period
16 June 2020 - 15 September 2020

FEEDBACK: OPEN

UPCOMING

Commission adoption

Planned for
Fourth quarter 2020

About this initiative

Summary The EU is launching a new strategy to improve and accelerate patients' access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry.

It will address:

- the life cycle of medicines from R&D to authorisation and patient access
- how to put scientific and technological advances into practice
- how to fill market gaps (e.g. new antimicrobials)
- lessons learnt from COVID-19 on how to better prepare for future pandemics.

Topic Public health

Type of act Communication

Category Commission Work Programme

Roadmap

FEEDBACK: CLOSED

Type
Roadmap
[More about roadmaps](#)

Feedback period
02 June 2020 - 07 July 2020 (midnight Brussels time)

2b. Click 'Go to consultation' (to view the consultation and acquaint further)

Roadmap

Feedback period
02 June 2020 - 07 July 2020

FEEDBACK: CLOSED

Public consultation

Feedback period
16 June 2020 - 15 September 2020

FEEDBACK: OPEN

UPCOMING

Commission adoption

Planned for
Fourth quarter 2020

Public consultation

ALL FEEDBACK (242)

FEEDBACK: OPEN

Feedback period
16 June 2020 - 15 September 2020 (midnight Brussels time)

The Commission would like to hear your views.

Through public consultations you can express your views on aspects of EU laws and policies before the Commission finalises its proposals.

[Go to consultation >](#)

Commission adoption

Type
Communication
[More about adopted acts](#)

Planned for
Fourth quarter 2020

Subscribe to receive notifications

Be notified by email when new initiatives are added on topics you're interested in or follow developments to individual initiatives.

You can manage your subscription preferences whenever you like.

[Log in](#) [Register](#)

2c. After clicking 'Go to consultation' you will be directed to this website page:

<https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12421-Pharmaceutical-Strategy-Timely-patient-access-to-affordable-medicines/public-consultation>

Click 'respond to the questionnaire' to access the question sheet.

PAGE CONTENTS

About this consultation

Target audience

Why we are consulting

Responding to the questionnaire

Contact

Why we are consulting

Medicines play an important role in assuring diagnosis, treatment and prevention of diseases. We as citizens across the EU expect to benefit from equal access to safe, innovative and affordable therapies because our health often depends on them. If treatments are not available due to shortages or because we simply cannot afford them, our health can be compromised. The Commission intends to design a plan that will address the current issues of access, availability and affordability of medicines, while still promoting sustainable innovation and support EU industry to remain an innovator and world leader. It also aims to strengthen the current system and help it respond to public health threats such as the coronavirus pandemic, without compromising patient safety. This plan will be a new Pharmaceutical Strategy for Europe, scheduled for adoption by the end of the year. In order to ensure that all possible views are considered in the design of this strategy and to ensure transparency and accountability, the European Commission invites all interested individuals or organisations to share their views and experiences and contribute to the development of a plan putting Europeans at the centre.

Responding to the questionnaire

You can contribute to this consultation by filling in the online questionnaire. If you are unable to use the online questionnaire, please contact us using the email address below.

Questionnaires are available in some or all official EU languages. You can submit your responses in any official EU language.

For reasons of transparency, organisations and businesses taking part in public consultations are asked to register in the EU's [Transparency Register](#).

[Respond to the questionnaire >](#)

Personal data and privacy statement

The European Union is committed to protecting your personal data and to respecting your privacy. When carrying out public consultations we adhere to the policy on 'protection of individuals with regard to the processing of personal data by the Community institutions', based on [Regulation \(EU\) 2018/1725](#) on processing of personal data by the EU institutions.

Further information on the [protection of your personal data](#)

2d. After clicking **'Respond to the questionnaire'** you will be directed to log-in at your EU account and after fill-in the survey:

<https://ec.europa.eu/eusurvey/runner/EUPharmaStrategy?surveylanguage=en>

STEP 3: Provide your inputs

The consultation is addressed to individual citizens, patients, and carers replying in their personal capacity as well as health professionals and organisations involved in cancer prevention, diagnosis, treatment, follow-up care and research.

Drawing on your input, the Commission will go on to complement this initial roadmap consultation with further targeted interactions with specific stakeholder groups.

Below attached input for feedback outlines one section for which the European Commission needs input for the Pharmaceutical Strategy for Europe. **See example below and find at the end of this guide hyperlinked references to the key messages of relevance to the childhood cancer community.**

3a. Fill in **'Beginning'**

- Choose **'Language of my contribution'** – express your views in your native language or choose the common English language.
- Fill in **'the questionnaire'** – express your views about the 'Pharmaceutical Strategy' and unmet needs of Paediatric Oncology community by providing answers on 24 questions.

About you

* Language of my contribution

English ▼

* I am giving my contribution as

▼

* Which stakeholder group do you represent?

▼

Are you responding on behalf of a Small or Medium Sized Enterprise?

- Yes
 No

* First name

Marko

* Surname

Ocokoljic

* Email (this won't be published)

marko.ocokoljic@siope.eu

* Country of origin

📍 Please add your country of origin, or that of your organisation.

▼

* Publication privacy settings

📍 The Commission will publish the responses to this public consultation. You can choose whether you would like your details to be made public or to remain anonymous.

Anonymous

Only your type of respondent, country of origin and contribution will be published. All other personal details (name, organisation name and size, transparency register number) will not be published.

Guidance on filling in the survey is attached in the separate PDF document.

3b. 'Attach a file' (after filling in the questionnaire)

- If you have research or findings that support your ideas, you can add them as an attachment.
- Files can be **max 1 MB**. Allowed file types: **pdf, txt, doc, docx, odt, rt**.
- **'Upload the document'** and click **'Submit'** (to send your input on the questionnaire).

REFERENCE DOCUMENTS

- **SIOPE draft Public Consultation response on the Pharmaceutical Strategy for Europe:** [here](#)
- **SIOPE draft Roadmap Consultation response on the Pharmaceutical Strategy for Europe:** [here](#)

For any questions, please contact: olga.kozhaeva@siope.eu or marko.ocokoljic@siope.eu